



NOVAEYE
MEDICAL®

Half Year Report: For Half Year Ended December 31 2021



Consolidated Results for Announcement to the Market

For the half year ended 31 December 2021

This results announcement and the half-year report attached to this announcement should be read in conjunction with the annual financial report for the year ended 30 June 2021.

Current reporting period: Half-year ended 31 December 2021

Previous corresponding reporting period: Half-year ended 31 December 2020

			31 December 2021 \$'000
Revenues from ordinary activities	Down 2%	To	6,542
Consolidated Results			
(Loss) before interest, tax, depreciation and amortisation (EBITDA)	Up 170%	To	(2,201)
(Loss) for the period, before tax	Up 92%	To	(3,078)
(Loss) from ordinary activities after tax	Up 92%	To	(3,078)
Net (Loss) for the period attributable to members	Up 92%	To	(3,078)

Dividends (distribution)	Amount per security	Franked amount per security
Interim dividend	Nil	Nil
Previous corresponding period	Nil	Nil
Record date for determining entitlements to the dividend	N/A	N/A

OTHER INFORMATION

For the half-year ended 31 December 2021

	Half-year ended 31 December 2021	Half-year ended 31 December 2020
Net Tangible Assets per Security		
Net tangible asset backing per ordinary security (Excludes value attributable to goodwill, other intangible assets, deferred tax asset, capitalised development expenditure and related deferred grant income)	\$0.11	\$0.18

Dividends

Date the dividend (distribution) is payable

N/A

Record date to determine entitlements to the dividend (distribution)

N/A

If it is a final dividend, has it been declared?

N/A

Details of entities over which control has been gained or lost during the period

On October 27 2021, AlphaRET GmbH was incorporated. AlphaRET GmbH is a 100% owned subsidiary of Nova Eye Medical Limited based in Berlin, Germany.

Contents

Page

Directors' report	2
Auditor's independence declaration	4
Consolidated statement of profit or loss and other comprehensive income	5
Consolidated statement of financial position	6
Consolidated statement of changes in equity	7
Consolidated statement of cash flows	8
Notes to the consolidated financial statements	9
Directors' declaration	16
Independent auditor's review report	17
Corporate directory	19

Directors' Report

The directors of Nova Eye Medical Limited (the Company and the Group) submit herewith the financial report of Nova Eye Medical Limited and its subsidiaries (the Group) for the half-year ended 31 December 2021. In order to comply with the provisions of the *Corporations Act 2001*, the Directors report as follows:

The names of the directors of the Company during or since the end of the half-year are:

Name

Mr V Previn	Executive Chairman
Mr R Coupe	Independent Director
Mr M Southard	Non-executive Director
Mr T Spurling	Managing Director
Mr A Sundich (resigned 24 November 2021)	Non-executive Director

Simon Gray is the Company Secretary of the Company.

Principal Activities

The principal activities of the Company during the financial period were the design, development, service and marketing, sales, and distribution of medical devices to treat eye disease.

Review of Operations

For the six months ended 31 December 2021, Nova Eye Medical Limited (Nova Eye Medical) recorded a group loss after tax of \$3,078,000. This compares with a group loss of \$1,605,000 in the six months to 31 December 2020.

Sales revenue of \$6,542,000 for the period included growth of 1.6% compared with the prior period measured in constant currency. Favourable sales growth in Germany and China was offset partially in the glaucoma surgical device segment by sales decline in USA. Total group revenue, which includes a small amount of revenue for the AlphaRET 2RT division, fell by 2%. Investment in the expansion of the commercial team in Germany along with investment in clinical marketing to support the new product launch in the second half of the fiscal year 2022 have resulted in an increase in EBITDA loss from \$814,000 in the six months to 31 December 2020 to \$2,201,000 in the current period.

Dividend and Return of Capital

There were no dividends or return of capital events during the period

Acquisition of Key Glaucoma Patents

On 26 August 2021, Nova Eye Medical Limited completed a transaction with a US company, Innovative Glaucoma Solutions LLC (IGS) to acquire a portfolio of patents related to Glaucoma treatment. Total consideration was AUD \$2,753,309 (US\$2,000,000) in cash plus 1,736,653 in the issue of the company's shares with a fair value of AUD \$701,229 (US\$500,000).

Auditor's Independence Declaration

The auditor's independence declaration is included on page 4 of the half-year report.

Rounding of Amounts

The company is a company of the kind referred to in ASIC Instrument 2016/191. In accordance with that Class Order amounts in the directors' report and the half-year financial report are rounded off to the nearest thousand dollars, unless otherwise indicated.

Directors' Report

Signed in accordance with a resolution of directors made pursuant to s.306 (3) of the *Corporations Act 2001*.

On behalf of the Directors

A handwritten signature in black ink, appearing to read 'V. Previn', is written over a light grey horizontal line.

Victor Previn
Chairman
Adelaide, 16 February 2022



Auditor's Independence Declaration

As lead auditor for the review of Nova Eye Medical Limited for the half-year ended 31 December 2021, I declare that to the best of my knowledge and belief, there have been:

- (a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (b) no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Nova Eye Medical Limited and the entities it controlled during the period.

A handwritten signature in black ink, appearing to be 'M. T. Lojszczyk', written over a light blue horizontal line.

M. T. Lojszczyk
Partner
PricewaterhouseCoopers

Adelaide
16 February 2022

Consolidated Statement of Profit or Loss and Other Comprehensive Income for the half-year ended 31 December 2021

	Note	Consolidated Group	
		2021 \$'000	2020 \$'000
Revenue		6,542	6,644
Other income	11	1,687	891
Changes in inventories of finished goods and work in progress		184	305
Raw materials and consumables used		(2,808)	(2,411)
Employee benefits expense		(3,283)	(2,953)
Depreciation and amortisation expense		(845)	(754)
Facilities expense		(792)	(438)
Legal expenses		(308)	(230)
Advertising and marketing expense		(902)	(291)
Finance costs		(33)	(37)
Realised foreign exchange gain/(loss)		(34)	224
Travel expense		(221)	(110)
Consulting fees		(1,274)	(1,981)
Other expenses		(991)	(464)
(Loss for the period) before tax		(3,078)	(1,605)
Income tax benefit/ (expense)		-	-
(Loss) for the period after tax		(3,078)	(1,605)
Other comprehensive income:			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Exchange differences on translating foreign operations from continuing operations (tax: nil)		1,077	(961)
Total comprehensive (loss)/income for the period		(2,001)	(2,566)
Earnings per share:			
Basic (cents per share)		(2.13)	(1.12)
Diluted (cents per share)		(2.13)	(1.12)
From profit attributable to the ordinary equity holders of the company:			
Basic (cents per share)		(2.13)	(1.12)
Diluted (cents per share)		(2.13)	(1.12)

Notes to the financial statements are included on pages 9 to 15.

Consolidated Statement of Financial Position as at 31 December 2021

	Note	Consolidated Group	
		31 Dec 2021 \$'000	30 June 2021 \$'000
Current assets			
Cash and cash equivalents		13,445	17,801
Trade and other receivables	8	1,967	4,020
Income tax refund receivable		-	1,408
Inventories		3,423	2,901
Prepayments		101	196
Total current assets		18,936	26,326
Non-current assets			
Trade and other receivables		66	64
Property, plant and equipment		1,281	1,334
Lease right of use asset		1,940	2,172
Intangible assets	9	7,009	3,443
Capitalised development expenditure		9,366	8,655
Total non-current assets		19,662	15,668
Total assets		38,598	41,994
Current liabilities			
Trade and other payables		1,354	2,003
Borrowings and lease obligations	10	523	1,938
Provisions		927	746
Total current liabilities		2,804	4,687
Non-current liabilities			
Borrowings and lease obligations	10	1,538	1,760
Provisions		-	76
Deferred tax liability		136	136
Total non-current liabilities		1,674	1,972
Total liabilities		4,478	6,659
Net assets		34,120	35,335
Equity			
Issued capital		37,391	36,678
Reserves		144	(2,235)
Accumulated (losses)/ profits		(3,415)	892
Total Equity		34,120	35,335

Notes to the financial statements are included on pages 9 to 15.

Consolidated Statement of Changes in Equity for the for the half-year ended 31 December 2021

	Note	Issued capital \$'000	Other reserves \$'000	Foreign currency reserve \$'000	Accumulated (losses)/ profits \$'000	Total \$'000
Balance at 1 July 2020		78,311	-	(2,359)	24,634	100,586
Return of share capital		(41,644)	-	-	-	(41,644)
Payment of dividend		-	-	-	(19,386)	(19,386)
Employee share scheme	13	11	90	-	-	101
Total of transactions with owners		(41,633)	90	-	(19,386)	(60,929)
Profit / (Loss) for the period		-	-	-	(1,605)	(1,605)
Other comprehensive income		-	-	(961)	-	(961)
Total comprehensive income		-	-	(961)	(1,605)	(2,566)
Balance at 31 December 2020		36,678	90	(3,320)	3,643	37,091
Balance at 1 July 2021		36,678	121	(2,356)	892	35,335
Issue of share capital		701	-	-	-	701
Employee share scheme	13	45	40	-	-	85
Total of transactions with owners		746	40	-	-	786
Profit / (Loss) for the period		-	-	-	(3,078)	(3,078)
Transferred to Retained Earnings		-	-	-	-	-
Other comprehensive income		-	-	1,077	-	1,077
Total comprehensive income		-	-	1,077	(3,078)	(2,001)
Balance at 31 December 2021		37,424	161	(1,279)	(2,186)	34,120

Notes to the financial statements are included on pages 9 to 15.

Consolidated Statement of Cash Flows for the for the half-year ended 31 December 2021

	Note	Consolidated Group	
		Half-year ended 31 Dec 2021 \$'000	Half-year ended 31 Dec 2020 \$'000
Cash flows from operating activities			
Receipts from customers		6,580	6,122
Payments to suppliers and employees		(8,715)	(9,248)
Interest and other costs of finance paid		(33)	(37)
Income tax refund received		1,408	-
Net cash (used in)/provided by operating activities		(760)	(3,163)
Cash flows from investing activities			
Interest received		-	155
Payment for plant and equipment		(432)	(166)
Payment for intangible assets		(2,865)	(270)
Payments for capitalised development costs		(1,071)	(490)
Receipts from escrow – sale of business	8	2,015	-
Payment of finalisation of the sale of business		(1,000)	-
Payment for purchase of business		-	(991)
Net cash (used in)/provided by investing activities		(3,353)	(1,762)
Cash flows from financing activities			
Payment of leases		(188)	(145)
Payment of dividend		-	(19,386)
Repayment of capital		-	(41,644)
Net cash (used in)/provided by financing activities		(188)	(61,175)
Net (Decrease)/ increase in cash and cash equivalents		(4,301)	(66,100)
Cash and cash equivalents at the beginning of the period		17,801	95,649
Effects of exchange rate changes on the balance of cash held in foreign currencies		(55)	(73)
Cash and cash equivalents at the end of the financial year		13,445	29,476

Notes to the consolidated financial statements are included on pages 9 to 15

Notes to the financial statements

Notes to the Consolidated financial statements for the half-year ended 31 December 2021

Note 1: Basis of preparation

These general-purpose financial statements for the interim half-year reporting period ended 31 December 2021 have been prepared in accordance with requirements of the Corporations Act 2001 and Australian Accounting Standards including AASB 134: Interim Financial Reporting. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards.

Note 2: General information and basis of preparation

The condensed interim consolidated financial statements ('the interim financial statements') of the Group are for the six months ended 31 December 2021 and are presented in Australian Dollars, which is the functional currency of Nova Eye Medical Limited (the parent company). They do not include all of the information required in the annual financial statements in accordance with Australian Accounting Standards and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 June 2021 and any public announcements made by the Group during the half-year in accordance with continuous disclosure requirements arising under the Australian Securities Exchange Listing Rules and the Corporations Act 2001.

The interim financial statements have been approved and authorised for issue by the Board of Directors on 16 February 2022.

Note 3: Changes in accounting policies

The accounting policies adopted are consistent with those of the last financial statements for the year ended 30 June 2021.

There are no other standards that are not yet effective and that would be expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.

Note 4: Estimates

When preparing the interim financial statements, management undertakes a number of judgments, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgments, estimates and assumptions made by management, and will seldom equal the estimated results.

The judgments, estimates and assumptions applied in the interim financial statements, including the key source of estimate uncertainty were the same as those applied in the Group's last annual financial statements for the year ended 30 June 2021.

Impairment of non-financial assets

The Group tests whether non-financial assets (including capitalised development expenditure, intangible assets and property, plant and equipment), have suffered any impairment on an annual basis or on a specific triggering event.

As at 30 June 2021, the recoverable amount of the cash generating units (CGU's) for Glaucoma Surgical Devices was determined based on value-in-use calculations which require the use of assumptions. The calculations use cash flow projections based on financial budgets approved by management covering a five-year period.

As at 30 June 2021, the recoverable value of the 2RT® CGU was determined by assessing the fair value less cost of disposal (FVLCD) of the underlying assets, the 2RT® intellectual property ("IP").

The Group has performed a review of impairment indicators at 31 December 2021. No indicators of impairment as at 31 December 2021 were identified.

Note 5: Commitments

There is no commitment for the purchase of property, plant and equipment at 31 December 2021.

Note 6: Contingencies

There are no contingencies as of the date of this report.

Notes to the financial statements

Note 7: Events occurring after the interim period

No matters or circumstances have arisen since the end of the half year which significantly affected or could significantly affect the operations of the Group, the results of the operations or the state of affairs of the Group in the future financial years.

Note 8: Trade and other receivables

AUD \$2,015,000 held in escrow relating to the sale of the Ellex Laser & Ultrasound business was received on 31 July 2021.

Note 9: Acquisition of glaucoma patents

The details of assets acquired were as follows:

Under the terms of the transaction Nova Eye Medical paid cash consideration of AUD \$2,753,309 (US\$2,000,000) and issued 1,736,653 fully paid ordinary shares in the Company to IGS. The shares issued under the agreement are under voluntary escrow for a period of 12 months by IGS.

This asset belongs to the glaucoma segment and will be utilised in the development of new technologies/products to facilitate glaucoma treatment. For the period ended 31 December 2021 there has been no income recognised in relation to the acquired patents. Accordingly, the amortisation of this asset has not yet commenced.

Note 10: Borrowings & lease obligations

Borrowings include lease liabilities arising from the operating lease arrangements across the group. The Paycheck Protection Program loan of AUD \$1,448,922 (US\$1,068,000) for Nova Eye, Inc. was forgiven by the US Government during this period as part of COVID-19 stimulus measures.

Note 11: Other income

	Consolidated Group	
	Half-year ended 31 Dec 2021 \$'000	Half-year ended 31 Dec 2020 \$'000
Grant income – Payroll Protection Program (PPP) loan forgiven	1,449	-
Interest	21	736
Other income	217	155
Total other income	1,687	891

Notes to the financial statements

Note 12: Operating Segments

The Group has two business segments, 2RT® and Glaucoma surgical devices. Prior to the half year ended 31 December 2021 the Glaucoma surgical devices segment was named “iTrack™”. The Glaucoma surgical devices segment includes operating results of both the iTrack™ and Molteno surgical devices. The Molteno surgical device business was acquired August 2 2020.

(i) Segment performance

	AlphaRET \$'000	Glaucoma surgical devices \$'000	Total \$'000
Six months ended 31 December 2021			
Revenue from continuing operations			
External sales	54	6,488	6,542
Total segment revenue from continuing operations	54	6,488	6,542
Segment EBITDA	(812)	(1,362)	(2,174)
Depreciation and amortisation	(101)	(744)	(845)
Segment results	(913)	(2,106)	(3,019)
Unallocated items:			
• Corporate costs			(1,603)
• Finance costs			-
• Interest and other revenue			1,544
Net profit (loss) before tax from continuing operations			(3,078)
Six months ended 31 December 2020			
Revenue from continuing operations			
External sales	221	6,423	6,644
Total segment revenue from continuing operations	221	6,423	6,644
Segment EBITDA	(285)	(298)	(583)
Depreciation and amortisation	(79)	(675)	(754)
Segment results	(364)	(973)	(1,337)
Unallocated items:			
• Corporate costs			(1,346)
• Finance costs			(37)
• Interest and other revenue			1,115
Net profit (loss) before tax from continuing operations			(1,605)

Notes to the financial statements

Note 12: Operating Segments (Cont.)

(ii) Segment assets

	AlphaRET \$'000	Glaucoma surgical devices \$'000	Total \$'000
31 December 2021			
Segment assets – opening	7,933	13,017	20,950
Segment asset changes for the period:			
Net movement in segment assets	109	4,214	4,323
Total segment assets	8,042	17,231	25,273
Reconciliation of segment assets to group assets			
Inter-segment eliminations			-
Unallocated assets			13,325
Total group assets			38,598
Year ended 30 June 2021			
Segment assets – opening	7,210	12,371	19,580
Segment asset changes for the period:			
Net movement in segment assets	723	646	1,369
Total segment assets	7,933	13,017	20,950
Reconciliation of segment assets to group assets			
Inter-segment eliminations			-
Unallocated assets			21,044
Total group assets			41,994

Notes to the financial statements

(ii) Segment liabilities

	AlphaRET \$'000	Glaucoma surgical devices \$'000	Total \$'000
31 December 2021			
Segment liabilities – opening	450	6073	6,523
Segment liabilities changes for the period:			
Net movement in segment liabilities	178	(2,360)	(2,182)
Total segment liabilities	628	3,714	4,342
Reconciliation of segment liabilities to group liabilities			
Unallocated liabilities:			
Current tax payable			-
Deferred tax liability			136
Other unallocated liabilities			-
Total group liabilities			4,478
30 June 2021			
Segment liabilities – opening	222	4,084	4,306
Segment liabilities changes for the period:			
Net movement in segment liabilities	228	1,989	2,217
Total segment liabilities	450	6,073	6,523
Reconciliation of segment liabilities to group liabilities			
Unallocated liabilities:			
Current tax payable			-
Deferred tax liability			136
Other unallocated liabilities			-
Total group liabilities			6,659

Notes to the financial statements

Note 13: Share-based payments – performance rights and options

Employee Options

	Consolidated Group 31 December 2021	
	Average exercise price per share option	Number of options
Balance as at 1 July 2021	\$0.50	897,500
Granted during year	\$0.51	1,580,000
Exercised during year	-	-
Forfeited during year	-	-
Balance as at 31 December 2021	\$0.51	2,477,500
Vested and exercisable at 31 December 2021	-	-

Fair value of options granted

The assessed fair value at grant date of options granted was:

- Options granted 10 August 2021 \$0.03
- Options granted 17 September 2021 \$0.02

The fair value at grant date is determined using Black-Scholes Model. The model inputs for options granted during the period ended 31 December 2021 included:

August 10 2021 Options

- (a) Options are granted for no consideration and vest at specified dates, commencing August 10, 2021. Vested options are exercisable for a period of 36 months after vesting
- (b) Exercise price: \$0.50
- (c) Grant date: 10 August 2021
- (d) Expiry date: 36 months from the vesting date
- (e) Share price at grant date: \$0.42
- (f) Expected price volatility of the company's shares: 15%
- (g) Risk-free rate: 3%

September 17 2021 Options

- (a) Options are granted for no consideration and vest at specified dates, commencing September 17 2021. Vested options are exercisable for a period of 36 months after vesting.
- (b) Exercise price: \$0.53
- (c) Grant date: 17 September 2021
- (d) Expiry date: 36 months from the vesting date
- (e) Share price at grant date: \$0.41
- (f) Expected price volatility of the company's shares: 15%
- (g) Risk-free rate: 3%

Performance Rights

	Consolidated Group 31 December 2021
	Number of Performance rights
Balance as at 1 July 2021	85,000
Rights granted during year	393,000
Rights exercised during year	(131,000)
Rights forfeited during the year	-
Balance as at 31 December 2021	347,000

Notes to the financial statements

Expenses arising from share-based payment transactions

Total expenses arising from share-based payment transactions recognised during the period as part of employee benefit expense were \$84,900 (2020: \$101,026).

Note 14: Related parties

The Company has a lease agreement for a property at 107 Rundle St, Kent Town, South Australia with a company controlled by Victor Previn. The terms of the lease are in line with similar properties in the area. Total payments made pursuant to the lease agreement during the period ended 31 December 2021 are \$42,075 including GST.

The Company has entered into a consulting agreement for engineering services with Mr Nicholas Previn, a son of Mr Victor Previn. The services are being provided at commercial rates. Total payments made pursuant to the agreement during the period ended 31 December 2021 are \$54,761 including GST.

Directors' declaration

The directors declare that:

- (a) The financial statements and notes are in accordance with the *Corporations Act 2001*, including:
 - (i) complying with Accounting Standards, *Corporations Act 2001* and other mandatory professional reporting requirements, and
 - (ii) giving a true and fair view of the consolidated entity's financial position as at 31 December 2021 and of its performance for the half-year ended on that date.
- (b) In the directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the directors made pursuant to s.303 (5) of the *Corporations Act 2001*.

On behalf of the Directors

A handwritten signature in black ink, appearing to read 'V. Previn', is written over a light grey rectangular background.

Victor Previn
Chairman

Adelaide, 16 February 2022



Independent auditor's review report to the members of Nova Eye Medical Limited

Report on the half-year financial report

Conclusion

We have reviewed the half-year financial report of Nova Eye Medical Limited (the Company) and the entities it controlled during the half-year (together the Group), which comprises the consolidated statement of financial position as at 31 December 2021, consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows and for the half-year ended on that date, significant accounting policies and explanatory notes and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Nova Eye Medical Limited does not comply with the *Corporations Act 2001* including:

1. giving a true and fair view of the Group's financial position as at 31 December 2021 and of its performance for the half-year ended on that date
2. complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity* (ASRE 2410). Our responsibilities are further described in the *Auditor's responsibilities for the review of the half-year financial report* section of our report.

We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Responsibilities of the directors for the half-year financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement whether due to fraud or error.

PricewaterhouseCoopers, ABN 52 780 433 757
Level 11, 70 Franklin Street, ADELAIDE SA 5000, GPO Box 418, ADELAIDE SA 5001
T: +61 8 8218 7000, F: +61 8 8218 7999, www.pwc.com.au

Liability limited by a scheme approved under Professional Standards Legislation.



Auditor's responsibilities for the review of the half-year financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2021 and of its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

A handwritten signature in cursive script that reads 'PricewaterhouseCoopers'.

PricewaterhouseCoopers

A handwritten signature in cursive script, likely belonging to M. T. Lojszczyk.

M. T. Lojszczyk
Partner

Adelaide
16 February 2022

Corporate directory

Directors

Mr V Previn	Executive Chairman
Mr R Coupe	Independent Director
Mr M Southard	Non-executive Director
Mr T Spurling	Managing Director
Mr A Sundich (resigned 24 November 2021)	Non-executive Director

Company Secretary

Mr Simon Gray

Corporate Accountant

Mr Liam Cook

Registered Office

Nova Eye Medical Limited
ABN 15 007 702 927
107 Rundle St
KENT TOWN, South Australia, 5067
Phone: +61 8 8362 0193
Email: info@nova-eye.com

Auditors

PricewaterhouseCoopers
Level 11, Franklin Street
ADELAIDE, South Australia, 5000

Share Registry

Computershare Investor Services Limited
Level 5, 115 Grenfell Street
Adelaide, South Australia, 5000

GPO Box 1903
Adelaide, South Australia, 5001

Enquiries within Australia: 1300 556 161
Enquiries outside Australia: +61 3 9415 4000
Website: www.computershare.com

Investor Relations

Mr Mark Flynn
mflynn@nova-eye.com
Phone: +61 416 068 733

Websites:

www.nova-eye.com

Stock Exchange

The company Nova Eye Medical Limited is listed on the Australian Securities Exchange (ASX).
The ASX Code is: EYE

Corporate Governance Statement

<https://nova-eye.com/investors/corporate-governance/>